EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device Placement

Carmel Ashur, Li Qin, Karl E Minges, James V Freeman, Sana M Al-Khatib, Steven M Bradley, P Michael Ho, Wendy S Tzou, Paul D Varosy, Paul L Hess, Amneet Sandhu

Pacing and Clinical Electrophysiology · 2025

DOI: 10.1111/pace.70016 ↗

At a glance

Übersichtsarbeit in Pacing and Clinical Electrophysiology, 2025. Written by Carmel Ashur and 10 co-authors. Institution: Division of Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. Major MEDLINE topics: Defibrillators, Implantable, Pacemaker, Artificial, Atrial Fibrillation, Anticoagulants. Cited 1 times so far (Crossref); 35 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Small studies have described the safety of uninterrupted direct oral anticoagulant (DOAC) use in atrial fibrillation (AF) patients undergoing elective, cardiac implantable electronic device (CIED) placement. Real‐world practice patterns and associated outcomes remain poorly defined.

Objective

Describe DOAC usage trends following uncomplicated, outpatient CIED placement in AF patients and evaluate clinical outcomes based on DOAC status at discharge.

Methods

Using data from the National Cardiovascular Data Registry, AF patients with CHA 2 DS 2 ‐VASc ≥ 2 undergoing uncomplicated, outpatient CIED placement from April 2016 to December 2019 were stratified by DOAC prescription at discharge. Short and longer‐term temporal trends and post‐discharge outcomes were assessed using Centers for Medicare and Medicaid (CMS) claims.

Results

Among 59,169 AF patients with elevated thromboembolic eligible for DOAC therapy who underwent elective, new CIED implant or generator replacement, 32,025 (54.1%) were discharged on a DOAC. Annual rates of DOAC use at discharge increased from 47.0% in 2016 to 62.5% in 2019 ( p < 0.0001). Overall, patients discharged on DOAC had higher adjusted rates of pocket hematoma (0.51% vs. 0.33%, p = 0.0007) and lower rates of stroke (2.9% vs. 3.2%, p = 0.05) at 30‐days but no significant differences in device infection or need for revision at 30‐days or 1‐year. Those undergoing new CIED implant had higher rates of pocket hematoma at 30‐days (0.53% vs. 0.36%, p = 0.02) and need for device revision at 1‐year (1.6% vs. 1.3%, p = 0.04).

Conclusion

In AF patients undergoing CIED implantation, about half were discharged on DOACs, with increasing rates of DOAC resumption immediately following post‐CIED implantation over the study period. Those discharged on DOACs had modestly higher rates of pocket hematoma or need for device revision but similar risk of device infection.

Subjects

MeSH terms (MEDLINE)

Defibrillators, ImplantablePacemaker, ArtificialAtrial FibrillationAnticoagulantsHumansMaleFemaleAgedAdministration, OralRegistriesThromboembolismUnited StatesMiddle Aged

Substances

Anticoagulants

Authors and institutions

  • Division of Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA.
  • Division of Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
  • Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • Division of Cardiology, Allina Health Minneapolis Heart Institute, Minneapolis, Minnesota, USA.

Cite

APA

Ashur, C., Qin, L., Minges, K. E., Freeman, J. V., Al-Khatib, S. M., Bradley, S. M., Ho, P. M., Tzou, W. S., Varosy, P. D., Hess, P. L., & Sandhu, A. (2025). Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device Placement. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.70016

Vancouver

Ashur C, Qin L, Minges KE, Freeman JV, Al-Khatib SM, Bradley SM, et al. Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device Placement. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.70016

BibTeX
@article{Ashur2025,
  author = {Ashur, Carmel and Qin, Li and Minges, Karl E and Freeman, James V and Al-Khatib, Sana M and Bradley, Steven M and Ho, P Michael and Tzou, Wendy S and Varosy, Paul D and Hess, Paul L and Sandhu, Amneet},
  title = {Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device Placement},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2025},
  doi = {10.1111/pace.70016}
}
Start for free →